Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial
| Autor: | Dobromira Tyc-Szczepaniak, Lucyna Kepka, Berenika Trąbska-Kluch, Arkadiusz Sprawka, Karolina Osowiecka, B. Czeremszynska |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Brain tumor Radiosurgery law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Quality of life law Internal medicine Medicine Humans 030212 general & internal medicine Longitudinal Studies Prospective Studies Prospective cohort study Survival rate business.industry Brain Neoplasms General Medicine medicine.disease Prognosis Surgery Survival Rate Hair loss 030220 oncology & carcinogenesis Quality of Life Cranial Irradiation business human activities Brain metastasis Follow-Up Studies |
| Zdroj: | Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 20(2) |
| ISSN: | 1699-3055 |
| Popis: | A recent randomized trial (NCT01535209) demonstrated no difference in neurocognitive function between stereotactic radiotherapy of the tumor bed (SRT-TB) and whole brain radiotherapy (WBRT) in patients with resected single brain metastasis. Patients treated with SRT-TB had lower overall survival compared with the WBRT arm. Here, we compared the health-related quality of life (HRQOL) in patients who received WBRT vs. SRT-TB. A self-reported questionnaire was used to assess HRQOL (EORTC QLQ-C30 with the QLQ-BN20 module) before RT, 2 months after RT, and every 3 months thereafter. HRQOL results are presented as mean scores and compared between groups. Of 59 randomized patients, 37 (64%) were eligible for HRQOL analysis, 15 received SRT-TB, and 22 had WBRT. There were no differences between groups in global health status and main function scales/symptoms (except for drowsiness and appetite loss, which were worse with WBRT 2 months after RT). Global health status decreased 2 and 5 months after RT, but significantly only for SRT-TB (p = 0.025). Physical function decreased significantly 5 months after SRT-TB (p = 0.008). Future uncertainty worsened after RT, but significantly only for SRT-TB after 2 months (p = 0.036). Patients treated with WBRT had significant worsening of appetite, hair loss, and drowsiness after treatment. Despite higher symptom burden after WBRT attributed to the side effects of RT (such as appetite loss, drowsiness, and hair loss), global health status, physical functioning, and future uncertainty favored WBRT compared with SRT-TB. This may be related to the compromised brain tumor control with omission of WBRT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink